[pending] SUCRALFATE (SUCRALFATE)
Pending LLM rewrite. Source: FDA_DRUG D-0598-2025.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: Pending LLM scoring against the rubric.
Plain-English summary
CGMP Deviations: The recalling firm filed for Chapter 11 in September 2024. As a result, it cannot monitor the quality program and hence cannot assure that products meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess, rendering the products adulterated.
The recalled product
- Product
- SUCRALFATE (SUCRALFATE)
- Brand
- SUCRALFATE
- Manufacturer
- Amerisource Health Services LLC
- Category
- Drug — Drugs
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (7)
- Lot 1015038
- Exp Date 07/31/2025
- Lot 1015898
- Exp Date 09/30/2025
- Lot 1016873
- Exp Date 10/31/2025 and Lot 1023398
- Exp Date 07/31/2026.
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · SUCRALFATE
- SevereFDA Recalls Sucralfate Oral Suspension Due to Bacillus Cereus Contamination
FDA (Drugs) · 2023-10-25
- HighPrescription Drug Sucralfate Suspension Recalled for Out-of-Specification Potency
FDA (Drugs) · 2023-09-20
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-06-17
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27